Please assess the completion status of the following clinical trial:

Trial Title: Post-Operative Analgesic Effects of Local Wound Infiltration With Ketorolac After Inguinal Herniorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 75 years old undergoing elective unilateral inguinal herniorrhaphy at Ramathibodi hospital~* Patients who are ASA classification 1-2~* Patients who had normal liver function test : AST 5-34 U/L , ALT 0-55 U/L, ALP 40-150 U/L ,TB0.2-1.2 mg/dL ,DB 0.0-0.5 mg/dL~* Patients who are going the operation under general anesthesia~* Patients who undergoing herniorrhaphy with Lichtenstein Tension-Free Repair technique~Exclusion Criteria:~* Patients who had femoral hernia~* Patients who had history of NSAIDs allergy~* Patients with history of prior hernorrhaphy~* Patients who had history of GI bleeding and gastritis~* Patients who had infection~* Patients who had history of SLE, HIV, asthma , cardiovascular disease and chronic kidney disease(GFR\<60 ml/min/1.73m2)~* Patients with end stage disease~* Patients who are pregnant~* Patients who reject or withdrawal from research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ketorolac injections (Type: EXPERIMENTAL): Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
- bupivacaine (Type: ACTIVE_COMPARATOR): Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.

Based on this trial design, predict the completion outcome and termination type (if applicable).